Journal article
Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Abstract
BACKGROUND: The optimal number of 3-wk docetaxel plus prednisone (DP) cycles for metastatic castration-resistant prostate cancer (mCRPC) is unclear.
OBJECTIVE: A retrospective analysis of two clinical trials was performed to evaluate the association of the number of cycles with overall survival (OS).
Authors
Pond GR; Armstrong AJ; Wood BA; Brookes M; Leopold L; Berry WR; de Wit R; Eisenberger MA; Tannock IF; Sonpavde
Journal
European Urology, Vol. 61, No. 2, pp. 363–369
Publisher
Elsevier
Publication Date
February 2012
DOI
10.1016/j.eururo.2011.06.034
ISSN
0302-2838